As a result of this work, AXIN2 hypermethylation/silencing is proposed as a tractable biomarker of ligand-dependent tumours that may help prospectively stratify patients for therapies perturbing Wnt-pathway ligands, including PORCN inhibitors [341]. The gene discussed is AXIN2; the disease is neoplasm.